Vytorin(Ezetimibe/Simvastatin)
OGN
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Organon & Co.
$4.3M
Medicare cost, 2024
$4.3M
Medicare cost, 2024
Medicare drug plans spent $4.3 million on Vytorin (ezetimibe/simvastatin) in 2024, for 5,246 prescriptions and refills filled by 1,203 patients. California accounts for the most spending ($758,858, 18% of the total). It is made by Organon & Co. (OGN).
Medicare cost, 2024
$4.3M
-14.7% from 2023
Prescriptions
5,246
$819.22 per claim
Patients
1,203
1,354 prescribers
Total spending, 2024
$4.3M
$3,572.43 per patient
Questions and answers
How much does Medicare spend on Vytorin?
Medicare prescription drug plans paid $4.3M for Vytorin in 2024, for 5,246 prescriptions and refills to 1,203 patients (down 14.7% from 2023). The average cost per claim was $819.22.
Which state spends the most on Vytorin?
California had the highest Medicare cost for Vytorin in 2024: $759K for 947 claims, followed by New York ($469K).
Who prescribes Vytorin the most?
Alexander H Cohen, family practice in Darlington, SC, had the highest Medicare cost for Vytorin in 2024: 22 claims costing $17K.
Who makes Vytorin?
Vytorin is made by Organon & Co. (OGN), listed in the Medicare spending data as Organon LLC.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Vytorin was $4.3M in 2024, after a high of $5.6M in 2022.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Vytorin, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Alexander H Cohen Darlington, SC | Family Practice | 22 | Under 11 | $17K |
| Paige Gordon Syracuse, NY | Physician Assistant | 20 | Under 11 | $13K |
| Zack A Razek Wichita, KS | Internal Medicine | 28 | Under 11 | $11K |
| Dina Liberman Brooklyn, NY | Internal Medicine | 14 | Under 11 | $8,629 |
| Narine Arutyounian Glendale, CA | Family Practice | 20 | Under 11 | $8,498 |
| Chien Chiang New York, NY | Internal Medicine | 16 | Under 11 | $7,658 |
| Vardui Arutyunyan Glendale, CA | Family Practice | 20 | Under 11 | $7,332 |
| Vagharshak M Pilossyan Van Nuys, CA | Internal Medicine | 17 | Under 11 | $6,531 |
| Cesar H Trabanco Ponce, PR | Endocrinology | 15 | Under 11 | $5,961 |
| Gary Reznik Los Angeles, CA | Cardiology | 15 | Under 11 | $5,792 |
| Maria M Rosario Quebradillas, PR | General Practice | 13 | Under 11 | $5,167 |
| Thomas A Falco Riverhead, NY | Cardiology | 13 | Under 11 | $5,141 |
| Hovanes J Ter-Zakarian Los Angeles, CA | Family Practice | 13 | Under 11 | $5,020 |
| Oscar L Chien San Gabriel, CA | Internal Medicine | 13 | Under 11 | $5,020 |
| Mihir K Maniar Eatontown, NJ | Internal Medicine | 13 | Under 11 | $4,970 |
| David S Rubin Norwalk, CT | Infectious Disease | 13 | Under 11 | $4,945 |
| Joann H Lamb New Castle, PA | Family Practice | 11 | Under 11 | $4,941 |
| Jiong-Ming Hu Flushing, NY | Cardiology | 13 | Under 11 | $4,923 |
| Igor Chernyavskiy Brooklyn, NY | Pulmonary Disease | 14 | Under 11 | $4,867 |
| James K Ensor Germantown, TN | Internal Medicine | 13 | Under 11 | $4,803 |
| Edna G Melendez Reyes Caguas, PR | Endocrinology | 12 | Under 11 | $4,800 |
| Jose M Perez Garcia Barceloneta, PR | Internal Medicine | 12 | Under 11 | $4,787 |
| Jill K Couch Norton, VA | Internal Medicine | 12 | Under 11 | $4,745 |
| Jose Cumba Guerrero Toa Alta, PR | General Practice | 12 | Under 11 | $4,731 |
| Samuel B Akuoku Laurelton, NY | Internal Medicine | 12 | Under 11 | $4,638 |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 1,955 | 7,790 | 1,790 | $5.7M |
| 2023 | 1,546 | 6,154 | 1,406 | $5.0M |
| 2024 | 1,354 | 5,246 | 1,203 | $4.3M |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Organon LLC | 5,246 | $4.3M |
Codes
- National drug codes (packages)
- 8
- RxNorm concept IDs
- 1245420, 1245430, 1245441, 1245449, 476345
- Application numbers
- NDA021687
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 15,142 side-effect reports named ezetimibe and simvastatin, the active ingredient of Vytorin (reports from 2004 on). 9,504 of them (62.8%) were serious, 857 named a death and 4,789 named a hospital stay. The reactions named most often were nausea, drug ineffective and fatigue. 524 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
15,142
110 in 2025 (+12.2% from 2024)
Serious
62.8%
9,504 reports
Deaths named
857
5.7% of reports
Hospital stays
4,789
31.6% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Vytorin?
15,142 reports from 2004 through September 2026 named ezetimibe and simvastatin, the active ingredient of Vytorin. 9,504 of them (62.8%) were serious, 857 named a death and 4,789 named a hospital stay.
What are the most reported side effects of Vytorin?
1,013 reports named nausea, the reaction named most often, followed by drug ineffective (820) and fatigue (777). In the last 5 years the reaction named most often was fatigue (33 reports). A report can name several reactions.
How many side-effect reports named Vytorin in 2025?
110 reports were received in 2025 (+12.2% from 2024). 2026 so far: 87 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Vytorin caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Vytorin caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Makers on the stock market:
OGN·OGN drug pipeline - Drug approvals (1 approval on file for ezetimibe and simvastatin) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (ezetimibe and simvastatin) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.